Shares of clinical stage biotechnology company Longeveron Inc. (LGVN) are rising more than 20% Tuesday morning at $3.89.
Longeveron today reported long-term follow-up data from the Company’s ELPIS I trial of Lomecel-BTM for patients with hypoplastic left heart syndrome (HLHS).
The data showed that 100% of the 10 patients who participated in the ELPIS I trial survived and remained heart transplant-free for up to 5 years of age after receiving Lomecel-BTM during their Stage 2 surgery.
LGVN has traded in the range of $2.50 – 9.34 in the last 1 year.
Source: Read Full Article
Lates News:
-
Crypto Market Surges Ahead of Equities: Dr. Dragosch's Analysis
-
Bitcoin's $28,000 Hurdle Sparks Red Monday for Cryptocurrencies
-
$BTC: Crypto Influencer Says ‘Salvadoran Money Is Accepted Everywhere in Lugano’
-
US Senators Reintroduce Bill To Investigate Bitcoin Adoption In El Salvador
-
JPMorgan Chase Shares Rise 7% On Upbeat Q1 Results